STOCK TITAN

Fennec Pharmaceuticals Inc - FENC STOCK NEWS

Welcome to our dedicated news page for Fennec Pharmaceuticals (Ticker: FENC), a resource for investors and traders seeking the latest updates and insights on Fennec Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Fennec Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Fennec Pharmaceuticals's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.67%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.3%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.93%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.4%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.1%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.51%
Tags
Fennec Pharmaceuticals Inc

Nasdaq:FENC

FENC Rankings

FENC Stock Data

287.87M
15.29M
16.56%
55.03%
6.69%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Durham

About FENC

fennec pharmaceuticals inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the united states. its lead product pedmark, a formulation of sodium thiosulfate, which has completed the phase iii clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. the company was formerly known as adherex technologies inc. and changed its name to fennec pharmaceuticals inc. in september 2014. fennec pharmaceuticals inc. was founded in 1996 and is based in research triangle park, north carolina.